2026-01-01 - Analysis Report
Okay, let's break down this analysis of Recursion Pharmaceuticals (RXRX).

**0. Report Start**

**1. Return Rate Comparison & Alpha/Beta Analysis**

*   **Company Overview:** Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company using AI-enabled drug discovery to industrialize drug discovery.

*   **Return Rate Analysis:** RXRX has significantly underperformed the S&P 500 (VOO).

    *   RXRX Cumulative Return: -33.45%
    *   VOO Cumulative Return: +44.20%
    *   Divergence: -77.7%. This represents a substantial gap in performance. The relative divergence of 0.0 suggests it's at the very bottom of its divergence range relative to VOO over the observed period.

*   **Alpha/Beta Analysis:**

    *   **Year:** 2024-2026
    *   **CAGR:** -33.0% (Negative compound annual growth rate indicating significant losses)
    *   **MDD:** 81.0% (Maximum Drawdown indicates very high risk, with significant potential losses)
    *   **Alpha:** -78.0% (Significantly underperforming relative to its benchmark.)
    *   **Beta:** -0.1 (Low Beta suggests it is less sensitive to market movements. While Beta of -0.1 is relatively less sensitive to market movement, Alpha is important because it tells about performance with respect to benchmark)
    *   **Cap(B):** 2.1 (Company Size is 2.1B (Relatively Big Size Company))

**2. Recent Stock Price Fluctuations**

*   Current Price: 4.11
*   Last Market Price: 4.10, Previous Close: 4.11, Change: -0.24%
*   5-day SMA: 4.25
*   20-day SMA: 4.464
*   60-day SMA: 4.9403

*Analysis:* The stock price is below all three moving averages (5-day, 20-day, and 60-day), indicating a short-term and medium-term downtrend. The recent small price change of -0.24% indicates that this stock may not be worth pursuing at this time.

**3. RSI, PPO, and Expected Return Analysis**

*   **MRI:** 0.9 (Medium Investment): Suggests a relatively high risk associated with the stock. This may be from its current state in the stock market.
*   **RSI:** 33.33 (Approaching Oversold): Suggests that the stock may be temporarily undervalued.
*   **PPO:** -0.43 (Negative): Indicates a short-term downtrend.
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (225 shares - Very Safe - MRI:0.90): The model recommends allocating 100% of available cash to purchase the stock. While MRI is at 0.9, suggesting medium investment risk, the signal itself indicates "Very Safe", highlighting a potential conflict or a specific condition triggering the buy recommendation.
*   **Recent Divergence Change:** -1.3 (Negative): Indicates short-term downward momentum.
*   **Expected Return:** -577.6%: This is a *highly* negative expected return, suggesting significant concerns about the company's future performance.

**4. Recent News & Significant Events**

*   **[2025-12-30] Insider Selling, CEO Transition, Trial Catalyst:** Suggests potential internal issues or concerns, and upcoming catalysts could drive volatility.
*   **[2025-12-31] ARK Investment Buys Shares:** Cathie Wood's ARK Investment buying a significant number of shares is a positive signal, suggesting some investors see potential.
*   **[2025-12-29] Stock Plummets:** Indicates recent negative price action.
*   **[2025-12-31] CFO Sells Shares:** Insider selling can be a negative signal, suggesting the CFO might expect the stock price to decline.
*   **[2025-12-18] JPMorgan Upgrade, Trial Data Gains:** Positive news indicating potential upside based on analyst opinion and positive trial data.
*   **[2025-12-17] Opinions on Merger and Clinical Data:** Suggests the stock is sensitive to news regarding mergers and clinical trial results.

**4-2. Analyst Opinions**

*   **Consensus:** Hold (2.50)
*   **Target Price:** Average $7.00 (High $11.00, Low $3.00)
*   The analyst consensus is currently "Hold," but there is a wide range of target prices, indicating uncertainty among analysts.

**5. Recent Earnings Analysis**

| 날짜       | EPS   | 매출      |
| ---------- | ----- | --------- |
| 2025-11-05 | -0.36 | 0.01 B$   |
| 2025-08-05 | -0.41 | 0.02 B$   |
| 2025-05-05 | -0.50 | 0.01 B$   |
| 2024-11-06 | -0.34 | 0.03 B$   |
| 2025-11-05 | -0.34 | 0.03 B$ |

*Analysis:*  The company is consistently losing money per share (negative EPS). Revenue is low and fluctuating, showing an overall trend in unprofitability.

**6. Financial Information**

| Quarter      | Revenue   | Profit Margin |
| ----------- | -------- | -------------- |
| 2025-09-30 | $0.00B   | -194.74%       |
| 2025-06-30 | $0.02B   | -5.54%         |
| 2025-03-31 | $0.01B   | -47.31%        |
| 2024-12-31 | $0.00B   | -183.62%       |
| 2024-09-30 | $0.03B   | 53.69%         |

| Quarter      | Equity    | ROE      |
| ----------- | --------- | -------- |
| 2025-09-30 | $1.05B    | -15.50%  |
| 2025-06-30 | $0.92B    | -18.70%  |
| 2025-03-31 | $0.93B    | -21.68%  |
| 2024-12-31 | $1.03B    | -17.29%  |
| 2024-09-30 | $0.52B    | -18.27%  |

*Analysis:*
*   **Revenue and Profitability:** Revenue is inconsistent. Profit margins are predominantly negative, indicating that the company is not effectively converting revenue into profit.

*   **Capital and Profitability:** While the company has significant equity, the Return on Equity (ROE) is consistently negative, meaning the company is not generating profits from its equity.
**7. Comprehensive Analysis**

Recursion Pharmaceuticals (RXRX) presents a mixed picture.

**Negative Factors:**

*   **Significant Underperformance:** RXRX has dramatically underperformed the S&P 500.
*   **High Risk:** High MDD, negative CAGR.
*   **Negative Earnings and Profit Margins:** Consistent losses and negative profit margins raise serious concerns about the company's financial health.
*   **Negative Expected Return:** The highly negative expected return suggests the models are highly pessimistic about the company's prospects.
*   **Recent Stock Decline:** The stock is trading below its short-term and medium-term moving averages.
*   **Insider Selling:** The CFO selling shares can be a negative signal.
*   **CEO Transition, Trial Data Catalyst Shape Recursion Pharmaceuticals’ Outlook:** Recent headlines imply internal issues that may result in a more volatile stock price.
**Positive Factors:**
*   **ARK Investment Purchase:** A notable investor (Cathie Wood's ARK Investment) recently purchased a significant number of shares.
*   **JPMorgan Upgrade:** At least one analyst has recently upgraded the stock.
*   **Trial Data Gains:** Positive trial data could be a sign of future potential.
*   **Cash rich**: The company holds a lot of cash in its balance sheet (over 1 Billion dollar, which is almost half of market cap) and can endure many quarterly losses.

**Overall:**

RXRX is a high-risk, high-reward investment.  The company is clearly struggling financially, but there are some positive signals, such as the ARK investment and the JPMorgan upgrade.

**Recommendation:** Given the negative financial performance, underperformance compared to the S&P 500, negative expected returns, and the mixed analyst opinions, a cautious approach is warranted. Investors should carefully weigh the potential risks against the speculative potential upside. This stock is suitable only for risk-tolerant investors who are comfortable with significant potential losses. Due diligence and monitoring of future earnings reports, clinical trial results, and company announcements are essential.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.